Our products – Radioligand therapy and imaging

Our products – Radioligand therapy and imaging

PLUVICTO®

Our brand name for lutetium Lu 177 vipivotide tetraxetan

SmPC

France

• Pluvicto transparency notice (PDF 0.7 MB)
• Summary of product characteristics - Pluvicto (PDF 0.8 MB)

Poland

• Summary of product characteristics (PDF 0.5 MB)
• Patient information leaflet (PDF 0.3 MB)

 

---

LOCAMETZ®

Kit for the preparation of gallium Ga 68 gozetotide injection

SmPC

France

• Locametz transparency notice (PDF 0.7 MB)
• Summary of product characteristics - Locametz (PDF 0.5 MB)

Poland

• Summary of product characteristics (PDF 0.4 MB)
• Patient information leaflet (PDF 0.2 MB)

Spain

• Technical data

---

LUTATHERA®

Our brand names for lutetium Lu 177 dotatate / lutetium (177Lu) oxodotreotide

SmPC

 

Bulgaria

• Summary of product characteristics (PDF 1.1 MB)

Croatia

• Summary of product characteristics (PDF 1 MB)

Cyprus

• Summary of product characteristics (PDF 1.1 MB)

Denmark

• Summary of product characteristics (PDF 1 MB)

Estonia

• Summary of product characteristics (PDF 0.9 MB)

Finland

• Summaries of product characteristics (PDF 0.9 MB)

France

• Transparency notice (PDF 0.5 MB)
• Summary of product characteristics (PDF 1.0 MB)

Greece

• Summary of product characteristics (PDF 1.0 MB)

Iceland

• Summary of product characteristics (PDF 0.9 MB)

Israel

• Summary of product characteristics (PDF 0.5 MB)

Korea

• Product information (PDF 0.5 MB)

Latvia

• Summary of product characteristics (PDF 1 MB)

Lithuania

• Summary of product characteristics (PDF 1.1 MB)

Malta

• Summary of product characteristics (PDF 1.1 MB)

Norway

• Summary of product characteristics (PDF 0.9 MB)

Poland

• Summary of product characteristics (PDF 1.1 MB)

Portugal

• Summary of product characteristics (PDF 1 MB)

Romania

• Summary of product characteristics (PDF 1.1 MB)

Singapore

• Summary of product characteristics (PDF 0.9 MB)

Slovakia

• Summary of product characteristics (PDF 1.1 MB)

Slovenia

• Summary of product characteristics (PDF 1.1 MB)

Spain

• Technical data (PDF 0.9 MB)

Sweden

• Summary of product characteristics (PDF 0.9 MB)

United Kingdom – Northern Ireland

• Product information (PDF 0.9 MB)

---

NETSPOT®

Kit for the preparation of gallium Ga 68 dotatate injection

PI

United States

• Prescribing information (PDF 0.3 MB)

 

 

---

SOMAKIT TOC®

Kit for the preparation of gallium (Ga 68) edotreotide solution

SmPC

Bulgaria

• Summary of product characteristics (PDF 0.6 MB)

Croatia

• Summary of product characteristics (PDF 0.6 MB)

Cyprus

• Summary of product characteristics (PDF 0.7 MB)

Denmark

• Summary of product characteristics (PDF 0.6 MB)

Estonia

• Summary of product characteristics (PDF 0.5 MB)

Finland

• Summary of product characteristics (PDF 0.5 MB)

France

• Transparency notice (PDF 0.4 MB)
• Summary of product characteristics (PDF 0.6 MB)

Greece

• Summary of product characteristics (PDF 0.7 MB)

Iceland

• Summary of product characteristics (PDF 0.5 MB)

Latvia

• Summary of product characteristics (PDF 0.6 MB)

Lithuania

• Summary of product characteristics (PDF 0.5 MB)

Malta

• Summary of product characteristics (PDF 0.7 MB)

Norway

• Summary of product characteristics (PDF 0.6 MB)

Poland

• Summary of product characteristics (PDF 0.6 MB)

Portugal

• Summary of product characteristics (PDF 0.6 MB)

Romania

• Summary of product characteristics (PDF 0.6 MB)

Slovakia

• Summary of product characteristics (PDF 0.6 MB)

Slovenia

• Summary of product characteristics (PDF 0.6 MB)

Spain

• Technical data (PDF 0.5 MB)

Sweden

• Summary of product characteristics (PDF 0.5 MB)

United Kingdom – Northern Ireland

• Product information (PDF 0.5 MB)

---

LysaKare®

LysaKare® 25g/25g solution for reduction of renal (kidney) radiation exposure during peptide-receptor radionuclide therapy with Lutathera®

SmPC

Bulgaria

• Summary of product characteristics (PDF 0.4 MB)

Croatia

• Summary of product characteristics (PDF 0.3 MB)

Cyprus

• Summary of product characteristics (PDF 0.3 MB)

Denmark

• Summary of product characteristics (PDF 0.3 MB)

Estonia

• Summary of product characteristics (PDF 0.3 MB)

Finland

• Summary of product characteristics (PDF 0.3 MB)

France

• Transparency notice (PDF 0.5 MB)
• Summary of product characteristics (PDF 0.3 MB)

Greece

• Summary of product characteristics (PDF 0.3 MB)

Iceland

• Summary of product characteristics (PDF 0.3 MB)

Latvia

• Summary of product characteristics (PDF 0.3 MB)

Lithuania

• Summary of product characteristics (PDF 0.3 MB)

Malta

• Summary of product characteristics (PDF 0.3 MB)

Norway

• Summary of product characteristics (PDF 0.3 MB)

Poland

• Summary of product characteristics (PDF 0.3 MB)

Portugal

• Summary of product characteristics (PDF 0.3 MB)

Romania

• Summary of product characteristics (PDF 0.3 MB)

Singapore

• Summary of product characteristics (PDF 0.2 MB)

Slovakia

• Summary of product characteristics (PDF 0.3 MB)

Slovenia

• Summary of product characteristics (PDF 0.3 MB)

Sweden

• Summary of product characteristics (PDF 0.3 MB)

United Kingdom – Northern Ireland

• Product information (PDF 0.3 MB)

1. https://www.adacap.com/our-products/our-products-radioligand-therapy-and-imaging
2. https://www.adacap.com/sites/novartis_adacap/files/Avis-Transparence-Pluvicto.pdf
3. https://www.adacap.com/sites/novartis_adacap/files/CP_NPI_Pluvicto_1000MBq-mL_Soln_InjInf_18-Oct-23_French.pdf
4. https://www.adacap.com/sites/novartis_adacap/files/Pluvicto_ChPL.pdf
5. https://www.adacap.com/sites/novartis_adacap/files/Pluvicto_Ul.pdf
6. https://www.adacap.com/sites/novartis_adacap/files/Avis-Transparence-Locametz.pdf
7. https://www.adacap.com/sites/novartis_adacap/files/CP_NPI_Locametz_25microgram_null_02-Oct-23_French.pdf
8. https://www.adacap.com/sites/novartis_adacap/files/Locametz_ChPL.pdf
9. https://www.adacap.com/sites/novartis_adacap/files/Locametz_Ul.pdf
10. https://cima.aemps.es/cima/dochtml/ft/1221692001/FT_1221692001.html
11. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-bg.pdf
12. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-hr.pdf
13. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-el.pdf
14. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-da.pdf
15. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-et.pdf
16. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-fi.pdf
17. https://www.adacap.com/sites/novartis_adacap/files/CT-16606_LUTATHERA_PIC_INS_Avis3_CT16606.pdf
18. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-fr.pdf
19. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-el.pdf
20. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-is.pdf
21. https://www.adacap.com/sites/novartis_adacap/files/Lutathera_SPC_DEC2021.pdf
22. https://www.adacap.com/sites/novartis_adacap/files/Lutathera-Korea-Label_EN.pdf
23. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-lv.pdf
24. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-lt.pdf
25. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-mt.pdf
26. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-no.pdf
27. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-pl.pdf
28. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-pt.pdf
29. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-ro.pdf
30. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-en.pdf
31. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-sk.pdf
32. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-sl.pdf
33. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-es.pdf
34. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-sv.pdf
35. https://www.adacap.com/sites/novartis_adacap/files/lutathera-inn-lutetium-177lu-oxodotreotide-en.pdf
36. https://www.novartis.com/us-en/sites/novartis_us/files/netspot.pdf
37. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-bg.pdf
38. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-hr.pdf
39. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-el.pdf
40. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-da.pdf
41. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-et.pdf
42. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-fi.pdf
43. https://www.adacap.com/sites/novartis_adacap/files/CT-16063_SOMAKIT_TOC_PIC_INS_Avis1_CT16063-1.pdf
44. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-fr.pdf
45. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-el.pdf
46. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-is.pdf
47. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-lv.pdf
48. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-lt.pdf
49. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-mt.pdf
50. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-no.pdf
51. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-pl.pdf
52. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-pt.pdf
53. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-ro.pdf
54. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-sk.pdf
55. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-sl.pdf
56. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-es.pdf
57. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-sv.pdf
58. https://www.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-en.pdf
59. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-bg-2.pdf
60. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-hr-2.pdf
61. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-el-3.pdf
62. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-da-2.pdf
63. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-et-2.pdf
64. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-fi-2.pdf
65. https://www.adacap.com/sites/novartis_adacap/files/CT-18132_LYSAKARE_PIC_INS_AvisDef_CT18132.pdf
66. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-fr-6-v2.pdf
67. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-el-4.pdf
68. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-is-2.pdf
69. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-lv-2.pdf
70. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-lt-2.pdf
71. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-mt-2.pdf
72. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-no-2.pdf
73. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-pl-2.pdf
74. https://www.adacap.com/sites/novartis_adacap/files/RCM-LysaKare-April-2024.pdf
75. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-ro-2.pdf
76. https://www.novartis.com/sg-en/sites/novartis_sg/files/Lysakare-Aug2019.SIN-app310820-pdf_0.pdf
77. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-sk-2.pdf
78. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-sl-2.pdf
79. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-sv-2.pdf
80. https://www.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-en-4.pdf